Monday, December 1 | 3:30 p.m.-3:40 p.m. | M7-SSNMMI03-4 | Room S501
Bone tumor volume derived from prostate-specific membrane antigen (PSMA) PET/CT scans is associated with hematologic adverse events among prostate cancer patients undergoing lutetium-177 (Lu-177) PSMA-617 treatment, according to this presentation.
In this scientific session on prostate cancer, Alireza Ghodsi, MD, a postdoctoral research fellow at the University of Washington in Seattle, will present findings from a retrospective cohort study that included 237 patients with metastatic castration-resistant prostate cancer (mCRPC) who received a median of three cycles of Lu-177 PSMA-617 treatment between June 2022 and January 2025.
Thirty-seven patients (16%) experienced grade ≥ 3 anemia, 12 (5%) grade ≥ 3 leukopenia, and 16 (7%) grade ≥ 3 thrombocytopenia. A multivariable Cox regression analysis showed that PSMA-PET bone volume was significantly associated with the occurrence of grade ≥ 3 anemia (hazard ratio [HR] = 1.47, p = 0.031), grade ≥ 3 thrombocytopenia (HR = 2.74, p < 0.001) when adjusting for other baseline characteristics.
Additionally, baseline hematologic parameter levels were significantly associated with grade ≥ 3 adverse events during treatment.
“Higher PSMA-PET bone tumor volume was significantly associated with a higher risk of grade ≥ 3 anemia and thrombocytopenia in patients with mCRPC treated with Lu-PSMA when adjusted for other risk factors,” the researchers concluded.
This study was awarded a Trainee Research Prize among submissions by fellows by the RSNA.
